Emugrobart clinical trials
Also written RO7204239 and GYM329.
How each study uses emugrobart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses emugrobart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular AtrophyCompletedPhase 2/3Hoffmann-La RocheNCT05115110Written as RO7204239
- A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular DystrophyCompletedPhase 2Hoffmann-La RocheNCT05548556Written as RO7204239
- A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or ObesityActive, not recruitingPhase 1Hoffmann-La RocheNCT07137585Written as RO7204239
- A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related ComorbidityActive, not recruitingPhase 2Hoffmann-La RocheNCT06965413Written as RO7204239
- A Clinical Pharmacology Study to Evaluate the Effect of GYM329 on Disuse Muscle Atrophy in Healthy VolunteerCompletedPhase 1Chugai PharmaceuticalNCT04708847Written as GYM329
Codes
What other systems call emugrobart · ClinicalTrials.gg INT016861
- UNII (FDA) INA01972XVEMUGROBARTOne source FDA
- NCI Thesaurus C211774EmugrobartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | INA01972XV | EMUGROBART | One source FDA |
| NCI Thesaurus | C211774 | Emugrobart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.